Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on December 16, 2015. The report covers a specific event occurring on the same date regarding intellectual property developments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a non-financial corporate event.
Material Changes
On December 16, 2015, the U.S. Patent and Trademark Office issued Patent No. 9,163,229 B2 to the Company. The patent is entitled "Compositions, Methods and Kits for Isolating Nucleic Acids from Body Fluids Using Anion Exchange Media." It covers methods for the rapid separation and isolation of systemically derived ctDNA and the purification of nucleic acids from urine samples using anion exchange media.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the general context of the patent issuance. The primary disclosure is the successful acquisition of the patent.
Investor Verification Checklist
- Verify the exact scope and claims of U.S. Patent No. 9,163,229 B2.
- Confirm the commercial applicability of the anion exchange media methods for ctDNA isolation.
- Review the attached press release (Exhibit 99.1) for additional strategic context.
- Note the discrepancy between the requested company name (Cardiff Oncology) and the filing registrant (Trovagene).